Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Research And Development Expense of $254.9 thousand for the year ending 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -64.9% in Research And Development Expense from 2024 to 2025.
- This data is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Research And Development Expense has declined by 42.8%.
- Historical annual values: Fiscal year 2025: $254.9 thousand | Fiscal year 2024: $726.2 thousand | Fiscal year 2023: $898.1 thousand | Fiscal year 2022: $1.35 million | Fiscal year 2021: $1.74 million | Fiscal year 2020: $1.22 million | Fiscal year 2019: $820.9 thousand | Fiscal year 2018: $40.7 thousand | Fiscal year 2017: $467.3 thousand | Fiscal year 2016: $870.0 thousand | Fiscal year 2015: $2.09 million | Fiscal year 2014: $1.12 million | Fiscal year 2013: $879.9 thousand | Fiscal year 2012: $1.01 million | Fiscal year 2011: $1.33 million | Fiscal year 2010: $445.5 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: